

TABLE OF CONTENTS

HEADS OF AGENCIES – CMDH.....	1
HEADS OF AGENCIES – PAEDIATRIC REGULATION	1
EUROPEAN MEDICINES AGENCY (EMA)	1
NOTICE TO APPLICANTS.....	13
BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)	13
BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)	15
PEI - VIGILANZ (SPECIFIC FOR GERMANY)	15
PHARMEUROPA TEXTS FOR COMMENT.....	15

HEADS OF AGENCIES – CMDh

8 December

[NEW - 9-11 December CMDh agenda](#)

HEADS OF AGENCIES – PAEDIATRIC REGULATION

Article 45 work-sharing: [click here](#)

EUROPEAN MEDICINES AGENCY (EMA)

Date	Content	Status
12/12/2025	Document: Minutes of the CVMP meeting 4-6 November 2025	New
12/12/2025	Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Antimicrobials Working Party (AWP) 2026	New
12/12/2025	Event: HMA/EMA multi-stakeholder workshop on artificial intelligence (AI)	Updated
12/12/2025	Document: CTIS Simplification Task Force: topics for analysis	Updated
12/12/2025	Event: Clinical Trials Information System (CTIS) sponsor end user training programme - March 2026	New
12/12/2025	Event: 15th Industry Standing Group (ISG) meeting	Updated
12/12/2025	Document: Biomarkers in oncology indications approved in the EU: key facts	New
12/12/2025	Event: EMA multistakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU	New
12/12/2025	Medicine: Clopidogrel Viatris (previously Clopidogrel Taw Pharma) clopidogrel	Updated
12/12/2025	Medicine: Prialt ziconotide	Updated

Date	Content	Status
12/12/2025	Medicine: Synagis palivizumab	Updated
12/12/2025	Medicine: Azacitidine Mylan azacitidine	Updated
12/12/2025	Medicine: Libmyris adalimumab	Updated
12/12/2025	Medicine: Imaavy nipocalimab	Updated
12/12/2025	News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 December 2025	New
12/12/2025	News: New medicine to treat non-muscle invasive bladder cancer	New
12/12/2025	Medicine: Ranluspec ranibizumab	New
12/12/2025	Medicine: Gotenfia golimumab	New
12/12/2025	Medicine: Exdensur depemokimab	New
12/12/2025	Medicine: Jelrix autologous cartilage-derived articular chondrocytes, in-vitro expanded	Updated
12/12/2025	Medicine: Aumseqa Aumolertinib	New
12/12/2025	Medicine: mNexspike COVID-19 mRNA vaccine	New
12/12/2025	Medicine: Blarcamesine Anavex blarcamesine	New
12/12/2025	Medicine: Myqorzo aficamten	New
12/12/2025	Medicine: Anktiva nogapendekin alfa inbakicept	New
12/12/2025	Referral: Melatomed and associated names - referral melatonin	New
12/12/2025	Post-authorisation: Dovprela (previously Pretomanid FGK) - opinion on variation to marketing authorisation pretomanid	New
12/12/2025	Post-authorisation: Elucirem - opinion on variation to marketing authorisation gadopiclenol	New
12/12/2025	Post-authorisation: Vueway - opinion on variation to marketing authorisation gadopiclenol	New

Date	Content	Status
12/12/2025	Post-authorisation: Nucala - opinion on variation to marketing authorisation mepolizumab	New
12/12/2025	Post-authorisation: Hetlioz - opinion on variation to marketing authorisation tasimelteon	New
12/12/2025	Post-authorisation: Uplizna - opinion on variation to marketing authorisation inebilizumab	New
12/12/2025	Post-authorisation: Mounjaro - opinion on variation to marketing authorisation tirzepatide	New
12/12/2025	Post-authorisation: Eylea - opinion on variation to marketing authorisation aflibercept	New
12/12/2025	Post-authorisation: Winrevair - opinion on variation to marketing authorisation sotatercept	New
12/12/2025	Post-authorisation: Arexvy - opinion on variation to marketing authorisation recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E	New
12/12/2025	Post-authorisation: Vfend - opinion on variation to marketing authorisation voriconazole	New
12/12/2025	Post-authorisation: Simponi - opinion on variation to marketing authorisation golimumab	New
12/12/2025	Post-authorisation: Recarbrio - opinion on variation to marketing authorisation imipenem; cilastatin; relebactam	New
12/12/2025	Post-authorisation: Aspaveli - opinion on variation to marketing authorisation pegcetacoplan	New
12/12/2025	Medicine: Prevymis letermovir	Updated
12/12/2025	Event: Fourth European Medicines Agency - Medtech Europe bilateral meeting	Updated
12/12/2025	Page: Clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome - Scientific guideline	Updated
12/12/2025	Document: Guideline on the clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome - Revision 2	New

Date	Content	Status
12/12/2025	Document: Checklist for the submission of day +5 translations for a post-opinion linguistic review - veterinary	Updated
12/12/2025	Document: HMPC meeting report on European Union herbal monographs, guidelines and other activities - 17-19 November 2025	New
12/12/2025	Page: Union list of critical medicines	Updated
12/12/2025	Document: Questions and answers on the Union list of critical medicines	Updated
12/12/2025	Document: Union list of critical medicines	New
12/12/2025	Page: ICH E22 General considerations for patient preference studies - Scientific guideline	New
12/12/2025	Document: ICH E22 Guideline on general considerations for patient preference studies - Step 2b	New
12/12/2025	Document: CVMP work plan 2026	New
12/12/2025	Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Efficacy Working Party (EWP-V) 2026	New
12/12/2025	Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Environmental Risk Assessment Working Party (ERAWP) 2026	New
12/12/2025	Document: Work plan for the CVMP Novel Therapies & Technologies Working Party (NTWP) 2026	New
12/12/2025	Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Pharmacovigilance Working Party (PhVWP-V) 2026	New
12/12/2025	Document: Work plan for the European Sales and Use of Antimicrobials in veterinary medicine Working Group (ESUAvet WG) 2026	New
12/12/2025	Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Safety Working Party (SWP-V) 2025	New
12/12/2025	Document: Checklist for the submission of Day 215 product information annexes for a post-opinion linguistic review (Word file)	Updated
12/12/2025	Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2026	New
12/12/2025	Document: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Scientific Advice Working Party (SAWP-V) for 2026	New
12/12/2025	Page: Stability testing for applications for variations to marketing authorisation - Scientific guideline	Updated
12/12/2025	Document: Guideline on stability testing for applications for variations to a marketing authorisation - Revision 3	New
11/12/2025	Medicine: Teriflunomide Viatris (previously Teriflunomide Mylan) teriflunomide	Updated
11/12/2025	Medicine: Darunavir Viatris (previously Darunavir Mylan)	Updated

Date	Content	Status
	darunavir	
11/12/2025	Medicine: Tobi Podhaler tobramycin	Updated
11/12/2025	Medicine: Afstyla lonocotocog alfa	Updated
11/12/2025	Document: Highlights - 20th EMA Industry Platform meeting on the operation of EU pharmacovigilance legislation meeting	New
11/12/2025	Event: New variations guidelines: webinar for marketing authorisation holders (human)	New
11/12/2025	Medicine: Pifeltro doravirine	Updated
11/12/2025	Event: Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - February 2026	New
11/12/2025	Event: Virtual live hands-on training course for clinical trials sponsors using EudraVigilance system - May 2026	New
11/12/2025	Medicine: Veyvondi vonocog alfa	Updated
11/12/2025	Medicine: Hyrimoz adalimumab	Updated
11/12/2025	Medicine: Hefiya adalimumab	Updated
11/12/2025	News: EMA welcomes political agreement on new EU pharmaceutical legislation	New
11/12/2025	Medicine: Mounjaro tirzepatide	Updated
11/12/2025	Document: Members of the Coordinating group of European network of paediatric research at the European Medicines Agency (Enpr-EMA)	Updated
11/12/2025	Event: Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) – December 2025	Updated
11/12/2025	Document: Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (17 December 2025)	New
11/12/2025	Document: From laboratory to patients: How the safety of medicines is ensured in the European Union	Updated
11/12/2025	Document: Methodology European Specialised Expert Community (ESEC): Members	Updated
11/12/2025	PSUSA: PSUSA/00000177/202501 - periodic safety update report single assessment amlodipine / atorvastatin	New

Date	Content	Status
11/12/2025	Document: Methodology Working Party (MWP) interested parties meeting report, September 2025	New
11/12/2025	Event: First EMA/HMA multi-stakeholder forum on EudraVigilance and signal detection	Updated
11/12/2025	Document: Consolidated 3-year work plan for the Emergency Task Force (ETF)	Updated
11/12/2025	DHPC: Tranexamic acid - direct healthcare professional communication (DHPC) tranexamic acid	New
11/12/2025	Page: Questions and answers on post approval change management protocols - Scientific guideline	Updated
11/12/2025	Document: Questions and answers on post approval change management protocols (PACMP) - Revision 1	New
11/12/2025	Event: Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System	New
11/12/2025	Event: Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System	New
11/12/2025	Event: Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System	New
11/12/2025	Event: Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System	New
11/12/2025	Event: Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System	New
11/12/2025	Event: Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System	New
10/12/2025	Page: Guidance on good manufacturing practice and good distribution practice: Questions and answers	Updated
10/12/2025	Page: How to submit information on authorised and investigational medicines	Updated
10/12/2025	Document: Draft user manual for the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) user interface (XEVMPDweb)	New
10/12/2025	PIP: EMA/PE/0000183758 - paediatric investigation plan zimislecel	New

Date	Content	Status
10/12/2025	PIP: EMA/PE/0000183430 - paediatric investigation plan tralokinumab	Updated
10/12/2025	PIP: EMA/PE/0000183866 - paediatric investigation plan brexpiprazole	Updated
10/12/2025	PIP: EMA/PE/0000184400 - paediatric investigation plan dapagliflozin; eplerenone	New
10/12/2025	PIP: EMA/PE/0000183220 - paediatric investigation plan iclepertin	Updated
10/12/2025	PIP: EMA-002944-PIP01-20 - paediatric investigation plan 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid tris(hydroxymethyl)aminomethane salt (1:1) (PF-06882961)	Updated
10/12/2025	PIP: EMA-003104-PIP02-22 - paediatric investigation plan Favezelimab; pembrolizumab	Updated
10/12/2025	PIP: EMA-002979-PIP01-21 - paediatric investigation plan pamrevlumab	Updated
10/12/2025	PIP: EMA-001613-PIP04-21 - paediatric investigation plan tezepelumab	Updated
10/12/2025	PIP: EMA-001758-PIP01-15-M02 - paediatric investigation plan Lumicitabine	Updated
10/12/2025	Medicine: Aimovig erenumab	Updated
10/12/2025	Medicine: Livogiva teriparatide	Updated
10/12/2025	Medicine: Kovaltry octocog alfa	Updated
10/12/2025	Medicine: Libmeldy autologous CD34+ cells encoding ARSA gene	Updated
10/12/2025	Medicine: Eydenzelt aflibercept	Updated
10/12/2025	Page: Radiopharmaceuticals - Scientific guideline	Updated
10/12/2025	Document: Draft guideline on quality of radiopharmaceuticals - Revision 2	New
10/12/2025	Event: 20th industry stakeholder platform - operation of European Union (EU) pharmacovigilance	Updated
10/12/2025	Event: Annual open meeting of the European Network of Paediatric Research at EMA (Enpr-EMA) November 2025	Updated
10/12/2025	Medicine: Sirolimus TriviumVet sirolimus	New

Date	Content	Status
10/12/2025	Document: EMA procedural advice for medicinal products intended exclusively for markets outside the European Union in the context of co-operation with the World Health Organisation (WHO)	Updated
10/12/2025	Event: 2025 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA (Enpr-EMA)	New
10/12/2025	Document: Minutes of the CAT meeting 8-9 October 2025	New
10/12/2025	Document: Minutes of the CAT meeting 10-12 September 2025	New
10/12/2025	Page: Union Product Database	Updated
10/12/2025	Medicine: Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) pandemic influenza vaccine (H5N1) (live attenuated, nasal)	Updated
10/12/2025	Medicine: Rizmoic naldemedine	Updated
10/12/2025	Medicine: Libtayo cemiplimab	Updated
10/12/2025	Document: Article 57 product data	Updated
10/12/2025	Medicine: Esbriet pirfenidone	Updated
10/12/2025	Medicine: Cejemly sugemalimab	Updated
10/12/2025	Page: Medical devices	Updated
10/12/2025	Page: List of medicines under additional monitoring	Updated
10/12/2025	Document: List of medicinal products under additional monitoring	Updated
10/12/2025	Document: List of medicinal products under additional monitoring	Updated
09/12/2025	Page: Dextrans - Scientific guideline	Updated
09/12/2025	PIP: EMA/PE/0000182447 - paediatric investigation plan amlitelimab	Updated
09/12/2025	PIP: EMA/PE/0000183373 - paediatric investigation plan tadalafil; tamsulosin	New
09/12/2025	PIP: EMA/PE/0000183329 - paediatric investigation plan interleukin-23 receptor antagonist peptide	Updated
09/12/2025	PIP: EMA/PE/0000183137 - paediatric investigation plan encaleret	Updated
09/12/2025	PIP: EMA/PE/0000182808 - paediatric investigation plan zoliflodacin	Updated
09/12/2025	PIP: EMA/PE/0000183083 - paediatric investigation plan	New

Date	Content	Status
	(S)-(4-amino-1,3-dihydrofuro[3,4-c][1,7]naphthyridin-8-yl)(3-(4-(trifluoromethyl)phenyl)morpholino)methanone	
09/12/2025	PIP: EMA/PE/0000182525 - paediatric investigation plan modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens (V940/ mRNA-4157)	New
09/12/2025	PIP: EMA/PE/0000182462 - paediatric investigation plan bizalimogene ralaplasmid; mavilimogene ralaplasmid; rocakinogene sifuplasmid	New
09/12/2025	PIP: EMA/PE/0000182440 - paediatric investigation plan resiniferatoxin	New
09/12/2025	Medicine: Carbaglu carglumic acid	Updated
09/12/2025	Page: Cancer Medicines Forum	Updated
09/12/2025	Document: Mandate, objectives and rules of procedure for the Cancer Medicines Forum	New
09/12/2025	Medicine: Bimervax COVID-19 Vaccine (recombinant, adjuvanted)	Updated
09/12/2025	Document: Bimervax: Periodic safety update report assessment 30 September 2024 - 29 March 2025	New
09/12/2025	Medicine: Enzalutamide Viatrix enzalutamide	Updated
09/12/2025	Document: Concept paper on the guideline revision on good pharmacogenomic practice	Updated
09/12/2025	Medicine: Loargys pegzilarginase	Updated
09/12/2025	Event: European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations - 2025	Updated
09/12/2025	Document: Meeting summary - PCWP/HCPWP and all eligible organisations meeting 18 November 2025	New
09/12/2025	Medicine: Inbrija levodopa	Updated
09/12/2025	Medicine: Anzupgo delgocitinib	Updated
09/12/2025	Medicine: Gohibic vilobelimab	Updated
09/12/2025	Document: List of substances and products subject to worksharing for signal management	Updated
09/12/2025	Page: Combination Products Operational Group	Updated

Date	Content	Status
09/12/2025	Document: Combination Products Operational Group (COMBO) - Terms of reference	New
09/12/2025	Medicine: Kimmtrak tebentafusp	Updated
09/12/2025	Medicine: Opdivo nivolumab	Updated
09/12/2025	Medicine: Levetiracetam Accord levetiracetam	Updated
09/12/2025	Medicine: Dacogen decitabine	Updated
09/12/2025	Document: Consolidated 3-year rolling work plan for the Methodology Working Party 2026-2028	New
09/12/2025	News: New data on antimicrobials sales and use in animals in the EU	New
09/12/2025	Page: European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) annual surveillance reports	Updated
09/12/2025	Document: European sales and use of antimicrobials for veterinary medicine: Annual surveillance report for 2024	New
09/12/2025	Document: 3-year work plan for the joint CHMP/CVMP Quality Working Party 2026-2028	New
09/12/2025	Document: Consolidated 3-year rolling work plan for the Non-clinical domain 2026-2028	New
09/12/2025	Event: Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party	Updated
09/12/2025	Page: Questions and answers for biological medicinal products	Updated
09/12/2025	Document: New Approach Methodologies EU-IN Horizon Scanning Report	Updated
09/12/2025	Document: 3-year rolling work plan for the Biosimilar Medicinal Products Working Party 2026-2028	New
09/12/2025	Document: Alzheimer's disease EU-IN Horizon Scanning Report	Updated
09/12/2025	Document: 3-year work plan for the Biologics Working Party (BWP) 2026-2028	New
09/12/2025	Medicine: Aubagio teriflunomide	Updated
09/12/2025	Page: Development and manufacture of synthetic peptides - Scientific guideline	Updated
09/12/2025	Document: Guideline on the development and manufacture of synthetic peptides	New
09/12/2025	Event: 15th industry stakeholder platform on research and development support	Updated

Date	Content	Status
09/12/2025	Medicine: Eviplera emtricitabine; rilpivirine; tenofovir disoproxil	Updated
09/12/2025	Medicine: Abecma idecabtagene vicleucel	Updated
09/12/2025	Medicine: Kostaive zapomeran	Updated
09/12/2025	PIP: EMA-003580-PIP01-24 - paediatric investigation plan 6'-([1S,3S)-3-([5-(difluoromethoxy)-2-pyrimidinyl]amino)cyclopentyl]amino)-2H-[1,3'-bipyridin]-2-one (AZD0780)	New
09/12/2025	PIP: EMA-003564-PIP01-23 - paediatric investigation plan olorofim	New
09/12/2025	PIP: EMA-003558-PIP01-23 - paediatric investigation plan linaprazan glurate	New
09/12/2025	PIP: EMA-003588-PIP01-24 - paediatric investigation plan 7-ethyl-10-hydroxy-camptothecin	New
09/12/2025	PIP: EMA-003592-PIP01-24 - paediatric investigation plan gorilla adenovirus vector expressing HPV6 and HPV11 antigens (PRGN-2012)	New
09/12/2025	PIP: EMA-003614-PIP01-24 - paediatric investigation plan diazoxide choline	New
09/12/2025	Page: European Surveillance of Veterinary Antimicrobial Consumption (ESVAC): 2009 - 2023	Updated
08/12/2025	Document: Agenda - PDCO agenda of the 9-12 December 2025 meeting	New
08/12/2025	PIP: EMA-003556-PIP02-24 - paediatric investigation plan tulisokibart	New
08/12/2025	PIP: EMA-003556-PIP01-23 - paediatric investigation plan tulisokibart	New
08/12/2025	PIP: EMA-003506-PIP01-23 - paediatric investigation plan doruxapapogenum ralaplasmidum	New
08/12/2025	PIP: EMA-002978-PIP02-24 - paediatric investigation plan trastuzumab deruxtecan	New
08/12/2025	Herbal: Carvi fructus - herbal medicinal product Caraway fruit	Updated
08/12/2025	Herbal: Carvi aetheroleum - herbal medicinal product Caraway oil	Updated
08/12/2025	PIP: EMA/PE/0000225184 - paediatric investigation plan nirmatrelvir; ritonavir	Updated
08/12/2025	Herbal: Althaeae radix - herbal medicinal product Marshmallow Root	Updated
08/12/2025	Medicine: Palforzia defatted powder of Arachis hypogaea L., semen (peanuts)	Updated
08/12/2025	Medicine: Tecartus brexucabtagene autoleucel	Updated
08/12/2025	Medicine: Yescarta axicabtagene ciloleucel	Updated
08/12/2025	Medicine: Caprelsa vandetanib	Updated
08/12/2025	Document: Medicine shortage communication (MSC): Insulin lispro Sanofi (insulin lispro 100 units/ml solution for injection in cartridge and pre-filled pen)	New

Date	Content	Status
08/12/2025	Shortage: Insulin lispro Sanofi insulin lispro	New
08/12/2025	Medicine: Neulasta pegfilgrastim	Updated
08/12/2025	Medicine: Zubsolv buprenorphine; naloxone	Updated
08/12/2025	Medicine: Symkevi tezacaftor; ivacaftor	Updated
08/12/2025	Document: Programme - Joint HMA/EMA multi-stakeholder workshop on Patient Registries December 2025	Updated
08/12/2025	Document: Medicinal products for human use: monthly figures - November 2025	New
08/12/2025	Medicine: Xermelo telotristat ethyl	Updated
08/12/2025	Medicine: Scemblix asciminib	Updated
08/12/2025	Document: Agenda - HMA/EMA Annual Data Forum 2025	Updated
08/12/2025	Medicine: Filspari sparsentan	Updated
08/12/2025	Event: Committee for Medicinal Products for Human Use (CHMP): 08-11 December 2025	Updated
08/12/2025	Document: Annex to agenda of the CHMP meeting 8-11 December 2025	New
08/12/2025	Document: Agenda of the CHMP meeting 8-11 December 2025	New
08/12/2025	Document: Classification of changes (tracked changes)	Updated
08/12/2025	Document: Classification of changes	Updated
08/12/2025	Event: EMA workshop: Non-clinical data for regulatory decision-making on the efficacy of medical countermeasures	Updated
08/12/2025	Event: Quarterly System Demo - Q4 2025	Updated
08/12/2025	Page: Union Product Database: release notes	Updated
08/12/2025	Document: Release notes - production release version 1.7.2544 - 5 December 2025 - Veterinary Medicinal Products Regulation: Union Product Database	New
08/12/2025	Medicine: Ebglyss lebrikizumab	Updated
08/12/2025	Medicine: Lyfnua gefapixant	Updated
08/12/2025	Medicine: Eucreas vildagliptin; metformin	Updated
08/12/2025	PIP: EMA/PE/0000224486 - paediatric investigation plan amlodipine; ramipril; rosuvastatin	New
08/12/2025	PIP: EMA/PE/0000224202 - paediatric investigation plan Dengue tetravalent vaccine (live, attenuated)	Updated
08/12/2025	PIP: EMA/PE/0000221803 - paediatric investigation plan betula pendula pollen extract	New
08/12/2025	Document: Product Management Service (PMS) roadmap	Updated
08/12/2025	Page: Scientific publications	Updated

Date	Content	Status
08/12/2025	Event: EMA/HMA annual data forum	Updated
08/12/2025	Page: Good pharmacogenomic practice - Scientific guideline	Updated
08/12/2025	Page: Substance and product data management services	Updated
08/12/2025	Document: Call for user acceptance testers for the read functionality in the Public Product Management Service (PMS) Application Programming Interface (API)	New
08/12/2025	DHPC: Remsima - direct healthcare professional communication (DHPC) infliximab	New

NOTICE TO APPLICANTS

No updates since October 30th, 2025.

BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)

Date	Title
12.12.2025	Oxbryta: Überprüfung des Nutzen-Risiko-Verhältnisses Wirkstoff: Voxelotor Mit Veröffentlichung der Entscheidung der Europäischen Kommission am 09. Dezember 2025 wurde das Risikobewertungsverfahren zu Oxbryta (Voxelotor) abgeschlossen.
11.12.2025	Rote-Hand-Brief zu intravenösen Tranexamsäure-Formulierungen: Schwerwiegende, einschließlich tödlich verlaufender, Nebenwirkungen aufgrund einer versehentlichen intrathekalen Verabreichung Wirkstoff: Tranexamsäure Die Zulassungsinhaber informieren darüber, dass injizierbare Tranexamsäure-Formulierungen nur zur intravenösen Anwendung zugelassen sind.
10.12.2025	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 16.10.2025 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Gabapentin Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Gabapentin infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.

Date	Title
09.12.2025	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 15.10.2025 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Trimethoprim Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Trimethoprim infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.
09.12.2025	Informationen zu Einreichung und Genehmigung von Schulungsmaterial Aktualisierung der Hilfestellungsdokumente zur Einreichung und Genehmigung von behördlich genehmigten Schulungsmaterialien
08.12.2025	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 15.10.2025 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Propylthiouracil Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Propylthiouracil infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.
08.12.2025	Sitzung (8. Dezember 2025 per Videokonferenz) – Kurzprotokoll Sachverständigen-Ausschuss für Apothekenpflicht nach § 53 Absatz 1 AMG
08.12.2025	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 15.10.2025 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Vancomycin Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Vancomycin infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.

BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)

Date	Title
11.12.2025	Anzeigen von Medizinprodukten und In-vitro-Diagnostika Die Anzeigen von Medizinprodukten und In-vitro-Diagnostika im Zusammenhang mit dem Inverkehrbringen und dem Sicherheitsbeauftragten sind noch bis zum 28. Mai 2026 über das DMIDS zu erfassen.
11.12.2025	DiGA-Leitfaden (Stand: 10.12.2025, Version 3.6) Das Fast-Track-Verfahren für digitale Gesundheitsanwendungen (DiGA) nach § 139e SGB V

PEI - VIGILANZ (SPECIFIC FOR GERMANY)

No updates since November 28th, 2025.

PHARMEUROPA TEXTS FOR COMMENT

Information on Pharmedeuropa updates will be presented quarterly.

Trotz regelmäßiger Aktualisierung und sorgfältiger Überwachung der Veröffentlichungen können wir keine Haftung oder Garantie für die Aktualität, Richtigkeit und Vollständigkeit der hier bereitgestellten Informationen übernehmen.
Dieser Newsletter enthält Links zu anderen Websites. Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

Despite regular updating and careful monitoring of the publications, we cannot take any responsibility or guarantee for the topicality, correctness and completeness of the information provided here.
This Newsletter contains links to other websites. Despite careful control of the content we would like to point out that we are not liable for the contents of external web links. The editors of the respective websites are fully responsible for their contents.